Clinical Trial Update: Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 study of selumetinib combined with MK-2206 for refractory or advanced gallbladder and biliary tract cancers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Liver Cancer

Drugs mentioned

• MK-2206 (MK-2206)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder | Phase 2 | Status: WITHDRAWN